Back to top
more

Inovio Pharmaceuticals (INO)

(Delayed Data from NSDQ)

$5.54 USD

5.54
207,804

+0.02 (0.36%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $5.55 +0.01 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 20.59% and 44.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 92.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Castle Biosciences (CSTL) delivered earnings and revenue surprises of 293.75% and 24.38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

by Zacks Equity Research

Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.

Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -9.38% and 85.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Inovio (INO) points to a 146.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Inovio (INO) Moves 17.4% Higher: Will This Strength Last?

by Zacks Equity Research

Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 223.7% in Inovio (INO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.

Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of 7.14% and 13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up

by Zacks Equity Research

INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.

All You Need to Know About Inovio (INO) Rating Upgrade to Buy

by Zacks Equity Research

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -4.76% and 2.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

First Wave (FWBI) IND Filing Under FDA's Review, Stock Up

by Zacks Equity Research

First Wave's (FWBI) stock gains as FDA reviews its IND amendment for the planned phase II study of an enhanced enteric microgranule delivery formulation of adrulipase.

ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection

by Zacks Equity Research

Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.

bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook

by Zacks Equity Research

bluebird bio, Inc. (BLUE) updates on the launch of gene therapy Zynteglo and provides cash burn guidance for 2023.